These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 32914036)

  • 61. Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial.
    Katz MHG; Shi Q; Meyers J; Herman JM; Chuong M; Wolpin BM; Ahmad S; Marsh R; Schwartz L; Behr S; Frankel WL; Collisson E; Leenstra J; Williams TM; Vaccaro G; Venook A; Meyerhardt JA; O'Reilly EM
    JAMA Oncol; 2022 Sep; 8(9):1263-1270. PubMed ID: 35834226
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A predictive model for recurrence after upfront surgery in patients with resectable pancreatic ductal adenocarcinoma (PDAC) by using preoperative clinical data and CT characteristics.
    Tian N; Wu D; Zhu L; Zeng M; Li J; Wang X
    BMC Med Imaging; 2022 Jul; 22(1):116. PubMed ID: 35786426
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Baseline CT-based Radiomic Features Aid Prediction of Nodal Positivity after Neoadjuvant Therapy in Pancreatic Cancer.
    Elsherif SB; Javadi S; Le O; Lamba N; Katz MHG; Tamm EP; Bhosale PR
    Radiol Imaging Cancer; 2022 Mar; 4(2):e210068. PubMed ID: 35333131
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Imaging-Based Subtypes of Pancreatic Ductal Adenocarcinoma Exhibit Differential Growth and Metabolic Patterns in the Pre-Diagnostic Period: Implications for Early Detection.
    Zaid M; Elganainy D; Dogra P; Dai A; Widmann L; Fernandes P; Wang Z; Pelaez MJ; Ramirez JR; Singhi AD; Dasyam AK; Brand RE; Park WG; Rahmanuddin S; Rosenthal MH; Wolpin BM; Khalaf N; Goel A; Von Hoff DD; Tamm EP; Maitra A; Cristini V; Koay EJ
    Front Oncol; 2020; 10():596931. PubMed ID: 33344245
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Predictive Modeling for Voxel-Based Quantification of Imaging-Based Subtypes of Pancreatic Ductal Adenocarcinoma (PDAC): A Multi-Institutional Study.
    Zaid M; Widmann L; Dai A; Sun K; Zhang J; Zhao J; Hurd MW; Varadhachary GR; Wolff RA; Maitra A; Katz MHG; Herman JM; Wang H; Knopp MV; Williams TM; Bhosale P; Tamm EP; Koay EJ
    Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33291471
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Clinicopathological correlation of radiologic measurement of post-therapy tumor size and tumor volume for pancreatic ductal adenocarcinoma.
    Wei D; Zaid MM; Katz MH; Prakash LR; Kim M; Tzeng CD; Lee JE; Agrawal A; Rashid A; Wang H; Varadhachary G; Wolff RA; Tamm EP; Bhosale PR; Maitra A; Koay EJ; Wang H
    Pancreatology; 2021 Jan; 21(1):200-207. PubMed ID: 33221151
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma.
    Perri G; Prakash L; Qiao W; Varadhachary GR; Wolff R; Fogelman D; Overman M; Pant S; Javle M; Koay EJ; Herman J; Kim M; Ikoma N; Tzeng CW; Lee JE; Katz MHG
    JAMA Surg; 2020 Sep; 155(9):832-839. PubMed ID: 32667641
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
    Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A
    Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Computed Tomography-Based Biomarker Outcomes in a Prospective Trial of Preoperative FOLFIRINOX and Chemoradiation for Borderline Resectable Pancreatic Cancer.
    Koay EJ; Katz MHG; Wang H; Wang X; Prakash L; Javle M; Shroff R; Fogelman D; Avila S; Zaid M; Elganainy D; Lee Y; Crane CH; Krishnan S; Das P; Fleming JB; Lee JE; Tamm EP; Bhosale P; Lee JH; Weston B; Maitra A; Wolff RA; Varadhachary GR
    JCO Precis Oncol; 2019; 3():. PubMed ID: 32914036
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Multiparametric MRI for prediction of treatment response to neoadjuvant FOLFIRINOX therapy in borderline resectable or locally advanced pancreatic cancer.
    Kang JH; Lee SS; Kim JH; Byun JH; Kim HJ; Yoo C; Kim KP; Ryoo BY; Kim SC
    Eur Radiol; 2021 Feb; 31(2):864-874. PubMed ID: 32813104
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
    Michelakos T; Pergolini I; Castillo CF; Honselmann KC; Cai L; Deshpande V; Wo JY; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Nipp RD; Parikh A; Qadan M; Warshaw AL; Hong TS; Lillemoe KD; Ferrone CR
    Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection.
    Marchegiani G; Todaro V; Boninsegna E; Negrelli R; Sureka B; Bonamini D; Salvia R; Manfredi R; Pozzi Mucelli R; Bassi C
    Eur Radiol; 2018 Oct; 28(10):4265-4273. PubMed ID: 29679211
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma.
    Koay EJ; Lee Y; Cristini V; Lowengrub JS; Kang Y; Lucas FAS; Hobbs BP; Ye R; Elganainy D; Almahariq M; Amer AM; Chatterjee D; Yan H; Park PC; Rios Perez MV; Li D; Garg N; Reiss KA; Yu S; Chauhan A; Zaid M; Nikzad N; Wolff RA; Javle M; Varadhachary GR; Shroff RT; Das P; Lee JE; Ferrari M; Maitra A; Taniguchi CM; Kim MP; Crane CH; Katz MH; Wang H; Bhosale P; Tamm EP; Fleming JB
    Clin Cancer Res; 2018 Dec; 24(23):5883-5894. PubMed ID: 30082477
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial.
    Murphy JE; Wo JY; Ryan DP; Jiang W; Yeap BY; Drapek LC; Blaszkowsky LS; Kwak EL; Allen JN; Clark JW; Faris JE; Zhu AX; Goyal L; Lillemoe KD; DeLaney TF; Fernández-Del Castillo C; Ferrone CR; Hong TS
    JAMA Oncol; 2018 Jul; 4(7):963-969. PubMed ID: 29800971
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy.
    Amer AM; Zaid M; Chaudhury B; Elganainy D; Lee Y; Wilke CT; Cloyd J; Wang H; Maitra A; Wolff RA; Varadhachary G; Overman MJ; Lee JE; Fleming JB; Tzeng CW; Katz MH; Holliday EB; Krishnan S; Minsky BD; Herman JM; Taniguchi CM; Das P; Crane CH; Le O; Bhosale P; Tamm EP; Koay EJ
    Cancer; 2018 Apr; 124(8):1701-1709. PubMed ID: 29370450
    [TBL] [Abstract][Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.